Improving the current state of schizophrenia care
More than 24 million people worldwide are living with schizophrenia. Despite its global prevalence, schizophrenia is an often misunderstood, serious mental health condition. At Boehringer Ingelheim, we’ve made a long-term, generational commitment to transform the mental health landscape. That’s why we’re committed to supporting partner organizations in their efforts to reduce health inequalities faced by people living with schizophrenia and other serious mental health conditions.
Schizophrenia can impact people’s lives in many ways, from employment to personal relationships and even life expectancy. People living with schizophrenia often face many obstacles, from stigma they encounter on a daily basis, to limited treatment options and inadequate support services. In order for us to help tackle these barriers and ensure those living with schizophrenia are receiving the care they deserve, we need to gain an accurate picture of the current schizophrenia care landscape, and hear first-hand from those living with the condition.
The following reports feature testimonials from those living with or caring for someone with schizophrenia and provide insight into some of the current standards, advancements and challenges within schizophrenia care.
Reflecting on 10 years of progress in schizophrenia care
"Schizophrenia - Time to Commit to Policy Change" is a 2024 report issued by the Oxford Health Policy Forum (OHPF), a non-for-profit community interest company based in the UK. Ten years on from their original report, the OHPF published a report calling for a more comprehensive, recovery-based approach towards the management and care of people living with schizophrenia. Now in 2024, this update reflects advances made in the last ten years, encompassing improvements in practice standards, policy development, emerging sciences and what remains to be done to further improve the lives of those living with schizophrenia.
The report is supported by an independent medical educational grant from Boehringer Ingelheim.
Listening to the European schizophrenia community
"Rethinking Schizophrenia: Beyond the Voices" is a 2024 report issued by the European Brain Coucil (EBC), a non-profit organization based in Brussels. Based on insights and first-hand healthcare professionals, patients and carers in the European schizophrenia community, the report aims to offer tangible policy changes to improve the lives of people living with the condition. "Rethinking Schizophrenia" is a research-driven project led by EBC, which highlights the need to optimize the way we manage schizophrenia, and “Beyond the Voices” is the first report in the series.
The “Rethinking Schizophrenia” project was supported with a grant from Boehringer Ingelheim.
At Boehringer Ingelheim, through our long-term, generational commitment to redefine mental health care we continue to support research into the barriers, challenges and opportunities within schizophrenia care aiming to ensure better access to information, care, support and ultimately solutions to those living with this condition.